ClinicalTrials.gg
RecruitingNCT06666673ENCMSUpdated Oct 5, 2026

Effect of Neural Constraints on Movement in Stroke

An Early Phase 1 interventional study of Tizanidine and Placebo in Stroke, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Northwestern University · Early Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 2 months later.
Updated Oct 5, 2026Study documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Stroke by Northwestern University — 6 open to participants now, 8 under way, none of them phase 3. Stroke · Northwestern University.

Planned enrollment
9th of 20
64 · median 52
Started
2024
the only one that year
Phase 1
Only one
of the 24
Registered
22nd of 24
by date

Among the 24 studies in Stroke by Northwestern University, this one is the 9th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 1, and was the 22nd registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

6 of the 24 studies in Stroke by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 1,419 Stroke studies recruiting now, 695 (49%) set no upper age limit and 283 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Stroke by Northwestern University, or all of them as a file.
02

Study summary

This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.

Read the detailed description

Sixty-four individuals with stroke will be recruited. Efforts will be made to recruit the same participants for each protocol. A REDCap database for this study will be setup to manage every step involved in the protocol.

The experiment uses a two-arm, cross-over, double-blinded, pre-test-post-test, randomized controlled design. After confirming eligibility, all enrolled participants will be scheduled for one anatomic brain MRI data collection and 6 arm/ hand experiments: 2 for each aim, one with TIZ and the other with placebo. All experiments will take place on separate days at least one week apart. During each of the experimental sessions, the participant will complete the protocol both before and 1.5 hours after administration of either TIZ or a placebo. The order of using TIZ or a placebo will be double-blinded and randomized to balance the FMA of the participants who receive the TIZ or placebo during their first session. In Aim 1, individuals will perform various isometric tasks with their paretic upper limb while high-density surface electromyography is used to estimate the behavior of their motor units. In Aim 2, individuals will perform isometric shoulder abduction with their cortical activity estimated with electroencephalography and their muscle activity recorded with electromyography. In Aim 3, individuals will be placed in a novel robotic device and asked to produce various shoulder abduction torques while either being perturbed by the device to elicit stretch reflexes or asked to perform reaching and hand-opening tasks. For all aims, joint torque and surface electromyographic data will be obtained from each participant before and 1.5 hours after administration of placebo or Tizanidine. Additionally, electroencephalographic data will be obtained during the second aim and joint kinematics will be obtained in the third aim. In all aims, participants will be seated in a Biodex chair (System 3 ProTM; Shirley, New York, USA) with their paretic limb interfaced to a novel haptic device (NACT-3D, Plaisier et. al., 2023) to measure and manipulate the forces/torques experienced by the participant. Throughout each session, straps will be placed across the chest and waist to prevent unwanted movement. The total time from enrollment to completion of participants is expected to be 8-12 weeks, during which participants will be instructed to keep performing routine daily activities.

AE and SAE reporting Adverse event (AE) report form has been implemented in the RedCap database, which can be used at any time. The investigators will report all AEs to the Northwestern Institutional Review Board (IRB) per established policies and requirements. The investigators will create AE reports every six months to review for trends and troubleshoot any issues that arise and require study protocol revision. If any AEs are reported that require follow-up medical care, the investigators will immediately refer the participant back to his/her physician team.

Serious adverse events (SAEs) that are unanticipated, serious, and possibility related to the study intervention will be reported to the Independent Monitor(s), IRB, and National Institute of Child Health and Human Development (NICHD) in accordance with requirements. Unexpected fatal or life-threatening AEs related to the intervention will be reported to the Northwestern IRB in accordance with IRB requirements within 24 hours, and to the NICHD program Officer with 7 days. Other serious and unexpected AEs related to the intervention will also be reported to the Northwestern IRB in accordance with IRB requirements within 24 hours, and to the NICHD program Official within 15 days. Anticipated or unrelated SAEs will be handled in a less urgent manner but will be reported to the PIs, IRB, NICHD, and other oversight organizations in accordance with their requirements. In the annual AE summary, the PIs Report will state that they have reviewed all AE reports.

03

Conditions studied

  • Stroke

Keywords

  • Neurotransmitters
  • flexion synergy
  • brain plasticity
  • tizanidine
  • stroke
  • motor control
  • spasticity
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
  • Age between 18-80
  • Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66)
  • Ability to communicate, understand, and provide
  • Ability to elevate their limb against gravity up to at least 75 degrees of shoulder flexion and to generate active elbow extension
  • MRI compatible
  • Intact skin on the hemiparetic arm
  • Ability to sit for three hours.

Exclusion criteria

Exclusion Criteria:

  • Motor or sensory impairment in the non-affected limb (FMA\<66, filament >3.6)
  • Any brainstem and/or cerebellar lesion
  • untreated cardiovascular disease
  • History of neurologic disorder other than stroke that affects the arms
  • Any acute or chronic painful condition in the upper extremities or spine, indicated by a score ≥5 on a 10-point visual analog scale
  • Current use of a pacemaker
  • History of seizure
  • Chemo denervation: botulinum toxin injection to any portion of the paretic upper extremity within the last 6 months, or phenol/alcohol injections \<12 months before participation
  • Flexion contractures larger than 30 degrees in the elbow, wrist, metacarpophalangeal joints (MCP) and interphalangeal joints (IP) after stretching for 15 minutes
  • Current participation in any experimental rehabilitation or drug studies
  • Individuals with any known to Tizanidine or currently taking Tizanidine; - concurrent use of medications known to suppress central nervous system activity
  • pregnant women or women who are nursing.

Additionally, each participant will be asked to provide a list of their current medications and a medical screening questionnaire will be sent to their primary physician. Each participant's list of medications will be reviewed for possible interactions with the study drugs and, at the study physician's advice, will be excluded from the study or asked to withhold medications when applicable. A full list of potential drug interactions can be seen in "Medication Interactions", but concisely includes the following: medications with dopaminergic, serotonergic, or noradrenergic actions; central nervous system (CNS) depressants; antihypertensive/ antiarrhythmic agents; and hormonal medications/.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Placebo comparator
    Placebo

    One lactose pill will be administered as a control.

    Drug: Placebo

  • Active comparator
    Drug Probe

    4 mg Tizanidine

    Drug: Tizanidine

Interventions

  • Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.

    Also known as: Zanaflex®

  • DrugPlacebo

    Administered as control

06

What researchers measure

Primary outcomes

  1. Brace Height

    Brace height quantifies the amplification in motor unit discharge rate generated by PICs. Brace height is sensitive to the level of neuromodulatory drive received by motoneurons.

    Time frame: Before and 1.5 hours after administration of TIZ

  2. Cortico-muscular-coherence in beta band

    Cortico-muscular coherence (CMC) is a commonly used method to measure the synchronized activity between cortex and muscles. Specifically, betaband CMC has been reported to be linked to the use of corticospinal tract.

    Time frame: Before and 1.5 hours after administration of TIZ

  3. Difference in reaching distance under shoulder abduction load

    The difference in reaching distance under shoulder abduction (SABD) load measures the strength of flexion synergy.

    Time frame: Before and 1.5 hours after administration of TIZ

  4. Reflexive electromyograph activity prior to movement

    Reflexive electromyograph (EMG) activity will be calculated as the difference between perturbation-induced EMG amplitude and baseline EMG, averaged during three-time windows 1) before the perturbation -100- 0 ms pre-perturbation; 2) 25 - 75 ms (shortlatency stretch reflex) and 2) 75 - 125 ms (long latency stretch reflex) after the perturbation onset. Perturbations occur at rest before the onset of a regular ballistic reaching trial. EMG is then normalized by the maximal EMG of the corresponding muscle.

    Time frame: Before and 1.5 hours after administration of TIZ

Secondary outcomes

  1. Delta-F

    Delta-F quantifies hysteresis (i.e., prolongation, or persistence) in motor unit firing induced by persistent inward currents (PICs). Delta-F is less selective to the level of neuromodulatory drive, but also accounts for inhibitory synaptic inputs to motoneurons.

    Time frame: Before and 1.5 hours after administration of TIZ

  2. Cortico-muscular-coherence in alpha band

    Alpha-band cortico-muscular-coherence (CMC) has been reported to be linked to the use of cortico-reticulospinal tract. A decreased use of cortico-reticulospinal tract will indirectly reflect an increased use of corticospinal tract, when the require motor task is still performed successfully.

    Time frame: Before and 1.5 hours after administration of TIZ

  3. Cortical Laterality Index (LI)

    LI measures the relatively higher (close to 1) or lower (close to -1) cortical activity between the lesioned vs non-lesioned motor cortices. An increase in LI indicates a shift of cortical activity towards the lesioned motor cortices, and thus reflecting an increased use of corticospinal tract. Minimum value is -1 and maximum value is 1. Higher scores indicate increased use of corticospinal tract.

    Time frame: Before and 1.5 hours after administration of TIZ

  4. Difference in Hand hexagon area under SABD load

    Hand hexagon area (HHA), i.e. the polygon created by connecting the five fingers of the hand with the base of the palm together in a plane, measures hand opening ability. The difference in HHA under SABD load also measures the strength of flexion synergy, but more distally. The investigators hypothesize that the difference under load will become less following tizanidine administration.

    Time frame: Before and 1.5 hours after administration of TIZ

  5. Reflexive EMG activity during movement

    The investigators will calculate the reflexive EMG activity as in Hypothesis 3.2, but with the perturbation occurring during the onset of a ballistic reach.

    Time frame: Before and 1.5 hours after administration of TIZ

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Jun 2029, 58 months after the start.

Of 71 non-industry phase 1 interventional studies under Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 45. This study's planned 58 months is above that.

Counting every sponsor, half of 97 studies reached it within 20 months; a quarter within 7 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2024
First posted
Oct 30, 2024
StartActual
Aug 23, 2024
Primary completionEst.
Jun 30, 2029
CompletionEst.
Jul 31, 2029
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Documents
Show all 2 updates
  1. Oct 5, 2026
  2. Sep 30, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06666673
Responsible party
Jun Yao (Professor, Northwestern University) — Principal investigator
First posted
Oct 30, 2024
Start date
Aug 23, 2024
Primary completion
Jun 30, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Riegele Arceo
Contact
riegele.arceo@northwestern.edu
3129080847
Julius Dewald, DPT, PhD
principal investigator · Northwestern University
Jun Yao, PhD
principal investigator · Northwestern University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tizanidine

Start the discussion